Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : CellOrigin's investigational product SY001, a CAR-macrophage therapy, is currently in the process of completing the initial patient dosing in Phase I clinical trials for treating Neoplasms.
Product Name : SY001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 20, 2023